Muzinich & Company Cut Its Ofs Capital (OFS) Holding; Ani Pharmaceuticals (ANIP) Shorts Down By 6.61%

May 23, 2018 - By Adrian Erickson

Ani Pharmaceuticals Inc (NASDAQ:ANIP) had a decrease of 6.61% in short interest. ANIP’s SI was 704,000 shares in May as released by FINRA. Its down 6.61% from 753,800 shares previously. With 98,600 avg volume, 7 days are for Ani Pharmaceuticals Inc (NASDAQ:ANIP)’s short sellers to cover ANIP’s short positions. The SI to Ani Pharmaceuticals Inc’s float is 7.88%. The stock increased 1.15% or $0.71 during the last trading session, reaching $62.39. About 49,032 shares traded. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has risen 18.93% since May 23, 2017 and is uptrending. It has outperformed by 7.38% the S&P500.

Muzinich & Company decreased Ofs Capital Corp (OFS) stake by 19.67% reported in 2017Q4 SEC filing. Muzinich & Company sold 100,276 shares as Ofs Capital Corp (OFS)’s stock declined 4.38%. The Muzinich & Company holds 409,390 shares with $4.87 million value, down from 509,666 last quarter. Ofs Capital Corp now has $147.37M valuation. The stock decreased 0.45% or $0.05 during the last trading session, reaching $11.04. About 48,409 shares traded. OFS Capital Corporation (NASDAQ:OFS) has declined 23.43% since May 23, 2017 and is downtrending. It has underperformed by 34.98% the S&P500.

More news for OFS Capital Corporation (NASDAQ:OFS) were recently published by:, which released: “OFS Capital’s (OFS) CEO Bilal Rashid on Q1 2018 Results – Earnings Call Transcript” on May 04, 2018.‘s article titled: “OFS Capital Corporation Announces Date for Its First Quarter 2018 Earnings Release and Conference Call” and published on April 27, 2018 is yet another important article.

Investors sentiment increased to 1.3 in 2017 Q4. Its up 0.63, from 0.67 in 2017Q3. It improved, as 2 investors sold OFS shares while 8 reduced holdings. 5 funds opened positions while 8 raised stakes. 2.68 million shares or 8.24% less from 2.92 million shares in 2017Q3 were reported. Janney Montgomery Scott Ltd Com accumulated 124,389 shares or 0.02% of the stock. Moreover, Buckhead Limited Company has 0.23% invested in OFS Capital Corporation (NASDAQ:OFS). Yakira Management accumulated 33,072 shares. Shikiar Asset Mngmt holds 0.14% or 25,250 shares in its portfolio. Freestone Cap Hldgs Limited Liability Corporation holds 0.14% or 164,636 shares. Macquarie Group Inc Ltd reported 0% in OFS Capital Corporation (NASDAQ:OFS). Sigma Planning accumulated 0.01% or 12,624 shares. Morgan Stanley owns 0% invested in OFS Capital Corporation (NASDAQ:OFS) for 144,030 shares. Manufacturers Life Insur The holds 0% in OFS Capital Corporation (NASDAQ:OFS) or 666 shares. The Minnesota-based Punch Assocs Investment Mngmt has invested 0.26% in OFS Capital Corporation (NASDAQ:OFS). Us Bank & Trust De invested in 0% or 2,350 shares. Lsv Asset Management has 21,400 shares. Jpmorgan Chase & Communication holds 0% or 135,441 shares in its portfolio. Confluence Inv Mgmt Ltd Company invested in 440,377 shares. Tower Cap Limited Liability (Trc) holds 8,019 shares.

Analysts await OFS Capital Corporation (NASDAQ:OFS) to report earnings on August, 3. They expect $0.33 earnings per share, 0.00% or $0.00 from last year’s $0.33 per share. OFS’s profit will be $4.41M for 8.36 P/E if the $0.33 EPS becomes a reality. After $0.29 actual earnings per share reported by OFS Capital Corporation for the previous quarter, Wall Street now forecasts 13.79% EPS growth.

Among 3 analysts covering OFS Capital Corp (NASDAQ:OFS), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. OFS Capital Corp had 6 analyst reports since August 12, 2015 according to SRatingsIntel. As per Monday, March 27, the company rating was upgraded by Ladenburg Thalmann. Robert W. Baird downgraded it to “Neutral” rating and $13 target in Monday, August 7 report. Robert W. Baird maintained OFS Capital Corporation (NASDAQ:OFS) rating on Friday, November 3. Robert W. Baird has “Hold” rating and $13.0 target. The stock of OFS Capital Corporation (NASDAQ:OFS) has “Outperform” rating given on Tuesday, December 20 by Robert W. Baird. The rating was upgraded by Janney Capital to “Buy” on Wednesday, April 27. The company was upgraded on Wednesday, August 12 by Zacks.

More important recent ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) news were published by: which released: “ANI Pharma (ANIP) Agrees to Acquire Generic Products & Other Assets from Amneal Pharmaceuticals LLC and Impax …” on April 29, 2018, also published article titled: “ANI Pharmaceuticals buying assets from Amneal, Impax”, published: “Market Trends Toward New Normal in Viacom, Nutanix, ANI Pharmaceuticals, PACCAR, Cabot Oil & Gas, and Box …” on May 07, 2018. More interesting news about ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was released by: and their article: “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” with publication date: May 08, 2018.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States. The company has market cap of $735.35 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations. It currently has negative earnings. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.

Among 6 analysts covering ANI Pharma (NASDAQ:ANIP), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. ANI Pharma had 20 analyst reports since July 31, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Wednesday, February 22 by TH Capital. The stock has “Outperform” rating by Oppenheimer on Friday, July 31. As per Thursday, June 23, the company rating was initiated by Raymond James. The firm has “Buy” rating by TH Capital given on Monday, September 28. The rating was upgraded by Roth Capital to “Buy” on Monday, September 28. On Thursday, December 7 the stock rating was maintained by Canaccord Genuity with “Buy”. As per Friday, August 5, the company rating was maintained by Oppenheimer. TH Capital maintained the stock with “Neutral” rating in Tuesday, August 4 report. The company was downgraded on Wednesday, September 2 by TheStreet. The firm earned “Buy” rating on Friday, November 13 by Standpoint Research.

Investors sentiment decreased to 1.09 in Q4 2017. Its down 0.60, from 1.69 in 2017Q3. It dropped, as 13 investors sold ANI Pharmaceuticals, Inc. shares while 43 reduced holdings. 23 funds opened positions while 38 raised stakes. 6.25 million shares or 0.89% less from 6.31 million shares in 2017Q3 were reported. Teachers Retirement System Of The State Of Kentucky reported 1,400 shares or 0% of all its holdings. Hutchin Hill Lp holds 13,100 shares or 0.24% of its portfolio. Texas Permanent School Fund has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Principal Financial Gp reported 67,057 shares. State Of Tennessee Treasury Department holds 0% or 7,077 shares. Intrust Bancorp Na stated it has 0.13% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Moreover, Arizona State Retirement Sys has 0.01% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Matarin Capital Ltd Com stated it has 0.07% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). California-based Parallax Volatility Advisers L P has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Lsv Asset Mgmt holds 0% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 25,200 shares. Vanguard Grp Inc Inc invested in 0% or 481,229 shares. Parametric Assocs Ltd Company accumulated 0% or 15,360 shares. 20,101 were reported by Thomson Horstmann And Bryant Inc. Envestnet Asset Mgmt holds 3,281 shares. Proshare Advsrs Llc reported 7,733 shares stake.

OFS Capital Corporation (NASDAQ:OFS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News